GVK & QS partnership offers trial outcome data

By Nick Taylor

- Last updated on GMT

Related tags: Drug development, Rheumatoid arthritis, Clinical trial

Following a “significant increase in demand” GVK Biosciences has partnered with Quantitative Solutions (QS) to develop and market clinical trial outcome databases, which they believe can improve drug development.

By offering the databases the partners believe they can support quantitative drug development and provide clients with “valuable insights​” into research and marketing programmes.

The databases are designed to assist drug development teams conduct comparative efficacy and safety analysis, link biomarkers to clinical outcomes, predict trial results and develop differentiation strategies.

Sreeni Devidas, vice president of business development at GVK, explained that “the alliance with QS is a major step to create infrastructure that supports the now mandated model of quantitative drug development​”.

By providing this infrastructure Devidas believes the partners can maximise the usefulness of pharmacokinetic/pharmacodynamic modeling and simulation (M&S) and increase its value in the drug development process.

Developing databases

QS already has databases covering five indications, rheumatoid arthritis and psoriasis, chronic HCV, neuropathic pain, osteoporosis and major depression, and GVK will distribute these globally.

By capturing summary level data for the clinical safety and efficacy outcomes from publicly available data sources the partners intend to add to this portfolio with databases covering dyslipidemia, schizophrenia and Alzheimer’s.

The partners will also support the databases by providing customisation and consulting services to clients. By doing so they believe clients will have maximum flexibility and benefits.

QS claims there has been a “significant increase in demand​” for meta-analyses involving publically available data. Japp Mandema, founder and CEO of QS added that its “customers will benefit greatly from the integrated products and services this partnership provides​”.

Related news

Show more

Related products

show more

Paper vs ePRO Data Collection Methods

Paper vs ePRO Data Collection Methods

Signant Health | 19-Oct-2021 | Technical / White Paper

Are you curious why more Sponsors choose digital data collection methods over the traditional pen and paper? Read this recent white paper to discover the...

GLP Tissue Cross Reactivity Testing

GLP Tissue Cross Reactivity Testing

Precision for Medicine | 11-Oct-2021 | Product Brochure

Precision for Medicine's unique combination of research services and tissue procurement capabilities form the pillars of our GLP Tissue Cross Reactivity...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Related suppliers

Follow us


View more